Comparative Pharmacology
Head-to-head clinical analysis: APRESAZIDE versus LANORINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRESAZIDE versus LANORINAL.
APRESAZIDE vs LANORINAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apresazide is a combination of hydralazine, a direct-acting vasodilator that relaxes arteriolar smooth muscle, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
LANORINAL is a combination product containing acetaminophen, which inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors via its metabolite AM404; and butalbital, a barbiturate that enhances GABA-A receptor activity, producing sedative and anxiolytic effects.
1 capsule (hydralazine 25 mg / hydrochlorothiazide 25 mg) orally twice daily; may increase to 2 capsules twice daily if needed. Maximum: 4 capsules daily.
1-2 mg intravenously or intramuscularly every 2-4 hours as needed for pain.
None Documented
None Documented
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); Hydrochlorothiazide: 6-15 hours. Clinical context: Dosing interval typically 12 hours for hydralazine component.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in hepatic impairment.
Hydralazine: ~75% renal (metabolites), <10% unchanged; Hydrochlorothiazide: >95% renal (unchanged).
Renal: 30-50% unchanged; fecal/biliary: 50-70% as metabolites.
Category C
Category C
Antihypertensive
Antihypertensive